Crescent Biopharma, Inc.
CBIO · NASDAQ
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Valuation | ||||
| PEG Ratio | -13.03 | 11.63 | 12.33 | -11.89 |
| FCF Yield | -1.94% | -0.23% | -0.29% | -0.78% |
| EV / EBITDA | 0.00 | -381.07 | -336.26 | -115.87 |
| Quality | ||||
| ROIC | -264.45% | -100.13% | -108.11% | -75.96% |
| Gross Margin | 0.00% | 100.00% | 100.00% | 100.00% |
| Cash Conversion Ratio | 0.82 | 0.95 | 1.00 | 0.91 |
| Growth | ||||
| Revenue 3-Year CAGR | -100.00% | -79.49% | -80.53% | – |
| Free Cash Flow Growth | 10.87% | 25.01% | 19.06% | -46.28% |
| Safety | ||||
| Net Debt / EBITDA | 0.00 | 1.05 | 0.99 | 1.40 |
| Interest Coverage | 0.00 | 0.00 | 0.00 | 0.00 |
| Efficiency | ||||
| Inventory Turnover | 0.00 | 0.00 | 0.00 | 0.00 |
| Cash Conversion Cycle | 0.00 | 6,417.43 | 700.88 | 0.42 |